BC Week In Review | Apr 4, 2016
Clinical News

Darinaparsin: Phase II started

Solasia began an open-label, Asian Phase II trial to evaluate 300 mg/m 2 IV darinaparsin once daily for 5 consecutive days every 21 days in about 65 patients. The company has exclusive, worldwide rights to...
BC Week In Review | Sep 8, 2014
Company News

Ziopharm Oncology, Solasia deal

Ziopharm and Solasia amended a 2011 deal granting Solasia exclusive rights to develop and commercialize IV and oral darinaparsin ( ZIO-101 ) in 13 Asia-Pacific territories. Under the amended deal, Solasia now has exclusive, worldwide rights to...
BC Week In Review | Nov 7, 2011
Clinical News

Zinapar darinaparsin: Phase I started

Solasia began an open-label, Japanese Phase I trial to evaluate 200 and 300 mg/m 2 IV darinaparsin for 5 consecutive days in a 28-day cycle for up to 4 cycles in about 9 patients with...
BC Week In Review | May 16, 2011
Clinical News

Zinapar darinaparsin regulatory update

The European Commission granted Orphan Drug designation for Ziopharm's Zinapar darinaparsin to treat peripheral T cell lymphoma (PTCL). Ziopharm expects to begin a pivotal trial of the IV organic arsenic in PTCL in late 2011....
BC Week In Review | Mar 14, 2011
Company News

Solasia, Ziopharm Oncology deal

Ziopharm granted Solasia exclusive rights to develop and commercialize IV and oral darinaparsin in 13 Asia-Pacific territories. The IV organic arsenic compound is in Phase II testing for peripheral T cell lymphoma (PTCL), while the...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

Human Genome Sciences Inc. (NASDAQ:HGSI) gained $446 million in market cap last week on the approval of Benlysta belimumab, benefitting from a better label and pricing than investors had expected. The approval was announced post-market...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Elan Corp. plc (NYSE:ELN) was up $0.03 to $6.56 last week after the European Commission approved an MAA for Xeplion paliperidone palmitate from Johnson & Johnson (NYSE:JNJ) for the maintenance treatment of schizophrenia...
BC Extra | Mar 8, 2011
Company News

Ziopharm, Solasia in deal for darinaparsin

Ziopharm Oncology Inc. (NASDAQ:ZIOP) granted Solasia Pharma K.K. (Tokyo, Japan) exclusive rights to develop and commercialize IV and oral darinaparsin in 13 Asia-Pacific territories. The IV organic arsenic compound is in Phase II testing for...
BC Week In Review | Jan 31, 2011
Clinical News

Zinapar darinaparsin regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation for Ziopharm's Zinapar darinaparsin to treat peripheral T cell lymphoma (PTCL). Ziopharm expects to begin a Phase I trial of the IV organic arsenic...
BC Week In Review | Sep 27, 2010
Clinical News

Zinapar darinaparsin regulatory update

FDA granted Orphan Drug designation for Ziopharm's Zinapar darinaparsin to treat peripheral T cell lymphoma (PTCL). The company said it plans to "imminently" begin Phase I testing of the oral organic arsenic in combination therapy...
Items per page:
1 - 10 of 52